Edition:
United Kingdom

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

74.17EUR
4:38pm BST
Change (% chg)

€1.30 (+1.78%)
Prev Close
€72.87
Open
€73.05
Day's High
€74.50
Day's Low
€72.88
Volume
2,679,248
Avg. Vol
2,331,376
52-wk High
€80.44
52-wk Low
€63.25

About

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality... (more)

Overall

Beta: 0.93
Market Cap(Mil.): €108,903.00
Shares Outstanding(Mil.): 1,262.50
Dividend: 2.96
Yield (%): 3.43

Financials

  SASY.PA Industry Sector
P/E (TTM): 23.32 29.30 32.55
EPS (TTM): 3.70 -- --
ROI: 5.69 14.23 13.83
ROE: 8.50 15.46 15.25

Sanofi to cut U.S. insulin costs for some patients to $99 per month

NEW YORK Sanofi SA said on Wednesday it will cut the cost of its insulin products to $99 per month for uninsured patients and others who pay cash for it in the United States, as the French drugmaker contends with intense criticism over the high price of the life-sustaining diabetes medication.

10 Apr 2019

Sanofi to cut U.S. insulin costs for some patients to $99 per month

NEW YORK Sanofi SA said on Wednesday it will cut the cost of its insulin products to $99 per month for uninsured patients and others who pay cash for it in the United States, as the French drugmaker contends with intense criticism over the high price of the life-sustaining diabetes medication.

10 Apr 2019

Sanofi to cut U.S. insulin costs for some patients to $99 per month

NEW YORK, April 10 Sanofi SA said on Wednesday it will cut the cost of its insulin products to $99 per month for uninsured patients and others who pay cash for it in the United States, as the French drugmaker contends with intense criticism over the high price of the life-sustaining diabetes medication.

10 Apr 2019

FDA rejects Sanofi-Lexicon add-on pill for type 1 diabetes

The U.S. Food and Drug Administration declined to approve a drug developed by Sanofi SA and Lexicon Pharmaceuticals Inc intended for use with insulin in patients with type 1 diabetes, the companies said on Friday.

22 Mar 2019

UPDATE 1-FDA rejects Sanofi-Lexicon add-on pill for type 1 diabetes

March 22 The U.S. Food and Drug Administration declined to approve a drug developed by Sanofi SA and Lexicon Pharmaceuticals Inc intended for use with insulin in patients with type 1 diabetes, the companies said on Friday.

22 Mar 2019

FDA rejects Sanofi-Lexicon add-on pill for type 1 diabetes

March 22 The U.S. Food and Drug Administration declined to approve a drug developed by Sanofi SA and Lexicon Pharmaceuticals Inc intended for use with insulin in patients with type 1 diabetes, the companies said on Friday.

22 Mar 2019

Exclusive: Sanofi says working on CEO succession plan

PARIS Pharmaceuticals group Sanofi is working on a plan to find a new CEO in agreement and consultation with current chief executive Olivier Brandicourt, a spokesman for the French drugmaker told Reuters on Monday.

18 Mar 2019

Exclusive: Sanofi says working on CEO succession plan

PARIS Pharmaceuticals group Sanofi is working on a plan to find a new CEO in agreement and consultation with current chief executive Olivier Brandicourt, a spokesman for the French drugmaker told Reuters on Monday.

18 Mar 2019

BioNTech hires banks for IPO worth up to $800 million: sources

FRANKFURT BioNTech, Europe's largest unlisted biotech firm by staff numbers, has hired banks to prepare for an initial public offering (IPO) worth as much as $800 million as early as this year, people familiar with the plan told Reuters.

12 Mar 2019

BioNTech hires banks for IPO worth up to $800 million - sources

FRANKFURT BioNTech, Europe's largest unlisted biotech firm by staff numbers, has hired banks to prepare for an initial public offering (IPO) worth as much as $800 million (611.3 million pounds) as early as this year, people familiar with the plan told Reuters.

12 Mar 2019

Earnings vs. Estimates